Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial.

被引：10
|
作者：
Yuan, Zhongyu
Huang, Jia-Jia
Hua, Xin
Zhao, Jian-Li
Lin, Ying
Zhang, Yuan-Qi
Wu, Zhiyong
Zhang, Lehong
Bi, Xiwen
Xia, Wen
Zhong, Yong-Yi
Wang, Shu-Sen
Xu, Fei
Hong, Ruoxi
Jiang, Kuikui
Shi, Yanxia
Xue, Cong
An, Xin
机构：
[1] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Dept Med Oncol, Guangzhou, Guangdong, Peoples R China
[3] State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China
[4] Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[6] Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China
[7] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Breast Oncol, Guangzhou, Peoples R China
[8] Guangdong Med Univ, Affiliated Hosp, Guangzhou, Peoples R China
[9] Shantou Cent Hosp, Dept Breast Surg, Shantou, Peoples R China
[10] Guangzhou Med Univ, Affiliated Hosp 2, Guangzhou, Peoples R China
[11] Sun Yat Sen Univ, Ctr Canc, Guangzhou, Peoples R China
[12] Sun Yat Sen Univ, Ctr Canc, Dept Med, State Key Lab Oncol South China,Collaborat Innova, Guangzhou, Peoples R China
[13] Sun Yat Sen Univ, Ctr Canc, Dept Oncol, State Key Lab Oncol South China,Collaborat Innova, Guangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.1003
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1003
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer
    Fadi Farhat
    Joseph G. Kattan
    Marwan Ghosn
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 1069 - 1077
  • [42] Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy
    Kim, Ji-Won
    Kim, Jee Hyun
    Im, Seock-Ah
    Lee, Kyung-Hun
    Kim, Jin-Soo
    Kim, Tae-Yong
    Han, Sae-Won
    Jeon, Yoon Kyung
    Oh, Do-Youn
    Kim, Tae-You
    Park, In Ae
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (05) : 1023 - 1029
  • [43] Phase II Trial of Weekly Docetaxel, Vinorelbine, and Trastuzumab in the First-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer
    Infante, Jeffrey R.
    Yardley, Denise A.
    Burris, Howard A., III
    Greco, F. Anthony
    Farley, Cindy P.
    Webb, Charles
    Spigel, David R.
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2009, 9 (01) : 23 - 28
  • [44] Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy
    Ji-Won Kim
    Jee Hyun Kim
    Seock-Ah Im
    Kyung-Hun Lee
    Jin-Soo Kim
    Tae-Yong Kim
    Sae-Won Han
    Yoon Kyung Jeon
    Do-Youn Oh
    Tae-You Kim
    In Ae Park
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 1023 - 1029
  • [45] Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies
    Tommasi, Chiara
    Airo, Giulia
    Prattico, Fabiana
    Testi, Irene
    Coriano, Matilde
    Pellegrino, Benedetta
    Denaro, Nerina
    Demurtas, Laura
    Dessi, Mariele
    Murgia, Sara
    Mura, Giovanni
    Wekking, Demi
    Scartozzi, Mario
    Musolino, Antonino
    Solinas, Cinzia
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (07)
  • [46] Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial
    Wang, Changjun
    Lin, Yan
    Zhou, Yidong
    Mao, Feng
    Zhu, Hanjiang
    Guan, Jinghong
    Zhang, Xiaohui
    Shen, Songjie
    Huang, Xin
    Chen, Chang
    Yao, Ru
    Zhao, Jialin
    Sun, Qiang
    BMC CANCER, 2020, 20 (01)
  • [47] Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: study protocol of a randomized controlled trial
    Changjun Wang
    Yan Lin
    Yidong Zhou
    Feng Mao
    Hanjiang Zhu
    Jinghong Guan
    Xiaohui Zhang
    Songjie Shen
    Xin Huang
    Chang Chen
    Ru Yao
    Jialin Zhao
    Qiang Sun
    BMC Cancer, 20
  • [48] HER2-positive and Hormone Receptor-positive Metastatic Breast Cancer Significant Survival Advantage with Kadcyla in the Second Line
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (06) : 418 - 418
  • [49] Cost-effectiveness of pertuzumab and trastuzumab as a first-line treatment of HER2-positive metastatic breast cancer in China
    Wang, Hao
    Wang, Ye
    Gong, Ruixue
    Geng, Yuyu
    Li, Li
    ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (11) : 11382 - 11393
  • [50] Maintenance hormone therapy with letrozole after first-line chemotherapy in postmenopausal patients with hormone receptor-positive metastatic breast cancer
    Borrego, M. Ruiz
    De la Haba, J.
    Morales, S.
    Ramos, M.
    Velasco, A.
    Mendez, M.
    Carabantes, F.
    Barnadas, A.
    Garcia, M.
    Moreno, J. A.
    EJC SUPPLEMENTS, 2005, 3 (02): : 117 - 117
12345